Review Article

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease

Table 1

RNAi drugs in human clinical trials [113115].

CompanyProduct nameDiseaseTargetStage

AlnylamALN-RSV1Respratory syncytial virus infectionNucleocapsid (N) gene of RSV genomeExpanded
phase II
AlnylamALN-VSPLiver cancers and solid tumorsKinesin spindle protein (KSP), VEGFPhase I
AlnylamALN-TTR01TTR-mediated amyloidosisTTRPhase I
AlnylamALN-PCShypercholesterolemiaPCSK9Phase I
Benetec/City of HopeAIDS lymphomarHIV7-shI-TAR-CCR5RZPhase I
Calando PharmaceuticalsCALAA-01Cancer and solid tumorsM2 subunit of ribonucleotide reductase (RRM2)Phase I
Cequent PharmaceuticalsCEQ508FAPβ-CateninPhase I
Duke UniversityMetastatic melanomaLMP2, LMP7, and MECL1Phase I
OPKO HealthBevasiranibWet age-related macular degenerationVEGFExpanded
phase III
OPKO HealthBevasiranibDiabetic macular edemaVEGFPhase II
Quark PharmaceuticalsPF4523655/RTP801i14Wet age-related macular degenerationRTP801Phase II
Quark PharmaceuticalsPF4523655/RTP801i14Diabetic macular edemaRTP801Phase II
Quark PharmaceuticalsQPI-1002/Akli5/I5NPAcute kidney injuryP53Phase I/IIa
Quark PharmaceuticalsQPI-1002/DGFiDelayed graft function in kidney transplantationP53Phase I/II
Sirna Therapeutics (MERCK)/AllerganSirna-027/AGN-745Wet age-related macular degenerationVEGFRIPhase II
Silence TherapeuticsAtu027Lung cancersProtein kinase N3 (PKN3)Phase I
SENETEKBrain tumors glioblastomasTenascin-CPhase I
TekmiraApoB SNALPHigh LDL cholesterolApo B lipoproteinPhase I/II
TekmiraTKM-PLK1Advanced solid tumorPLK1Phase I
TransDerm, IncTD101Pachyonichia congenitaKeratin 6a (K6a)Phase I
University of Duisbur-EssenChronic myeloid leukaemiabcr-ablSingle patient
Gradalis, Inc.FANGAdvanced cancerFurinPhase I
Gradalis, Inc.FANGOvarianFurinPhase II
Gradalis, Inc.FANGMelanomaFurinPhase II
Gradalis, Inc.FANGColon cancerFurinPhase II